Tezspire Shows Promise in Phase III Trial for Nasal Polyps

Key Insights

• AstraZeneca and Amgen's Tezspire demonstrated a reduction in nasal polyp size and improved nasal congestion in a Phase III trial.
• The anti-TSLP agent, already approved for severe asthma, may be a potential new treatment option for nasal polyps.
• Positive results could lead to a second indication for Tezspire, expanding its therapeutic application.

AstraZeneca and Amgen's Tezspire, a first-in-class anti-thymic stromal lymphopoietin (TSLP) agent, has exhibited promising results in a Phase III trial for the treatment of nasal polyps. The study demonstrated that Tezspire significantly reduced the size of nasal polyps and improved nasal congestion in patients. These findings suggest that Tezspire, already approved for severe asthma, could potentially become a valuable treatment option for individuals suffering from nasal polyps.

The positive outcome of this Phase III trial may pave the way for a second indication for Tezspire. AstraZeneca and Amgen are planning to file Tezspire for nasal polyps based on the Phase III readout. If approved, this would broaden the therapeutic application of Tezspire and offer a new treatment avenue for patients with this condition.